Skip to main content

Thomas Eldridge Stinchcombe

Professor of Medicine
Medicine, Medical Oncology

Current Appointments & Affiliations


Professor of Medicine · 2017 - Present Medicine, Medical Oncology, Medicine
Member of the Duke Cancer Institute · 2016 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.

Journal Article Lung Cancer · September 2021 OBJECTIVES: Veliparib is a potent poly(ADP)-ribose polymerase (PARP) 1 and 2 inhibitor that impedes repair of DNA damage induced by cytotoxic and radiation therapies. This phase 1 study evaluated veliparib in combination with chemoradiotherapy in patients ... Full text Link to item Cite

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

Journal Article Cancer Treat Res Commun · 2019 INTRODUCTION: Retrospective studies have evaluated the approach of stereotactic radiotherapy (SRT) to address oligoprogression in patients with EGFR mutant NSCLC on TKI therapy, it has never been prospectively studied. MATERIALS AND METHODS: We treated 25 ... Full text Link to item Cite
View All Publications

Recent Grants


BI1479-0001

Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2023 - 2028

Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655

Clinical TrialPrincipal Investigator · Awarded by Nuvalent, Inc. · 2023 - 2027

Methods to improve efficiency and robustness of clinical trials using information from real-world data with hidden bias

ResearchCo Investigator · Awarded by Food and Drug Administration · 2023 - 2026

View All Grants

Education, Training & Certifications


University of Virginia, School of Medicine · 1995 M.D.